File(s) not publicly available
Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial
journal contribution
posted on 2023-02-10, 02:49 authored by N Cheng, A Mclaverty, B Nelson, C Markulev, MR Schäfer, M Berger, N Mossaheb, M Schlögelhofer, S Smesny, IB Hickie, GE Berger, EYH Chen, L De Haan, DH Nieman, M Nordentoft, A Riecher-Rössler, S Verma, R Street, A Thompson, HP Yuen, R Hester, Alison YungAlison Yung, PD Mcgorry, K Allott, GP AmmingerBackground
Cognitive impairments are well-established features of psychotic disorders and are present when individuals are at ultra-high risk for psychosis. However, few interventions target cognitive functioning in this population.
Aims
To investigate whether omega-3 polyunsaturated fatty acid (n−3 PUFA) supplementation improves cognitive functioning among individuals at ultra-high risk for psychosis.
Method
Data (N = 225) from an international, multi-site, randomised controlled trial (NEURAPRO) were analysed. Participants were given omega-3 supplementation (eicosapentaenoic acid and docosahexaenoic acid) or placebo over 6 months. Cognitive functioning was assessed with the Brief Assessment of Cognition in Schizophrenia (BACS). Mixed two-way analyses of variance were computed to compare the change in cognitive performance between omega-3 supplementation and placebo over 6 months. An additional biomarker analysis explored whether change in erythrocyte n−3 PUFA levels predicted change in cognitive performance.
Results
The placebo group showed a modest greater improvement over time than the omega-3 supplementation group for motor speed (ηp2 = 0.09) and BACS composite score (ηp2 = 0.21). After repeating the analyses without individuals who transitioned, motor speed was no longer significant (ηp2 = 0.02), but the composite score remained significant (ηp2 = 0.02). Change in erythrocyte n-3 PUFA levels did not predict change in cognitive performance over 6 months.
Conclusions
We found no evidence to support the use of omega-3 supplementation to improve cognitive functioning in ultra-high risk individuals. The biomarker analysis suggests that this finding is unlikely to be attributed to poor adherence or consumption of non-trial n−3 PUFAs.
History
Journal
BJPsych OpenVolume
8Article number
PII S2056472422005725Location
EnglandPublisher DOI
ISSN
2056-4724eISSN
2056-4724Language
EnglishPublication classification
C1 Refereed article in a scholarly journalIssue
5Publisher
CAMBRIDGE UNIV PRESSUsage metrics
Keywords
Science & TechnologyLife Sciences & BiomedicinePsychiatryCognitionclinical high riskearly interventionrandomised controlled trialpsychotic disordersYOUNG-PEOPLEFISH-OILSCHIZOPHRENIAOMEGA-3-FATTY-ACIDSRELIABILITYIMPAIRMENTONSETDIETMental HealthComplementary and Integrative HealthClinical ResearchSchizophreniaBehavioral and Social ScienceSerious Mental IllnessBrain DisordersPreventionClinical Trials and Supportive ActivitiesNutritionMental healthPublic Health and Health Services not elsewhere classifiedClinical Sciences not elsewhere classified
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC